Overview


According to FutureWise analysis the market for Acute Sinusitis is expected to register a CAGR of 8.10% from 2023-2031.

An infection of the sinuses is known as acute sinusitis. Rhinosinusitis is the word which is frequently used because the sinus passageways and nasal passages are connected. A clear set of treatment algorithms must be established for such a widespread diagnosis in light of recent recommendations, concerns about antibiotic resistance, and recommendations for the responsible use of antibiotics. There are different types of groups of rhinosinusitis, which can be identified as follows: Acute symptoms are those that last shorter than four weeks, subacute symptoms can linger for four to twelve weeks, chronic means having symptoms for more than a month. Four episodes that last less than four weeks and are recurrent, with complete symptom relief in between episodes.

Treatment of Acute Sinusitis consists of either antibiotic therapy or a period of watchful waiting so long as the certainty of reliable follow-up. There are slight variations between different expert committee guidelines. The American Academy of Otolaryngology Adult Sinusitis 2015 updated guideline recommends amoxicillin with or without clavulanate in adults as first-line therapy for 5 to 10 days in most adults. Treatment failure is noted if symptoms do not decrease within seven days or worsen at any time. The Infectious Disease Society of America Guidelines for Acute Bacterial Rhinosinusitis recommends amoxicillin with clavulanate as first-line therapy for 10 to 14 days in children and 5 to 7 days in adults. Treatment failure is noted if symptoms do not decrease after 3 to 5 days or worsen after 48 to 72 hours of therapy. The duration of treatment is unclear; however, treating for an additional seven days after symptoms resolve was their suggestion. The criteria for treatment failure are if symptoms do not decrease or worsen after 72 hours of therapy. If the patient cannot tolerate oral fluids, then the patient must be administered ceftriaxone 50m/kg. If the patient can take oral fluids the next day and improves, then the patient can transition to a verbal antibiotic course after that. 

FutureWise Market Research has published a report that provides an insightful analysis of Acute Sinusitis Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts’ projects that Acute Sinusitis Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.
  • Sanofi
  • Abbott
  • Bayer AG
  • Aurobindo Pharma
  • Bristol Myers Squibb
  • Merck KGaA
  • AstraZeneca
  • Reddy’s Laboratories, Ltd.
  • Novartis AG
  • GlaxoSmithKline plc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Development in Acute Sinusitis Market:

  • In July 2022, Optinose unveiled the outcomes of their pre-planned analyses conducted as part of the ReOpen trial program, which assessed the effectiveness of XHANCE in treating patients with chronic sinusitis. XHANCE is a medication-device combination product that combines their proprietary Exhalation Delivery System (EDS), designed to deliver medication deep into nasal passages, with an anti-inflammatory drug.
  • In August 2021, GlaxoSmithKline obtained approval from the Food and Drug Administration (FDA) for Nucala (mepolizumab) to treat Chronic Rhinosinusitis with nasal polyps.

Seasonal variation is the leading cause of Acute rhinitis, commonly seen during certain seasons, such as the fall and winter. These seasonal changes are bound to drive demand for over-the-counter (OTC) cold remedies, including antihistamines, decongestants, and cough syrups. After the COVID-19 pandemic, significant changes have been made, and it had played a vital role in increasing awareness of the importance of hygiene, such as handwashing and mask-wearing, causing a reduction in the transmission of common cold viruses, leading to a potential decrease in acute rhinitis cases. Moreover, this awareness could also drive demand for preventive products. Ongoing research and development have been increased after COVID-19 into antiviral drugs, vaccines, and other treatments for common cold viruses, which may result in new and more effective therapies. The public bodies are playing a crucial role in providing the funds for the R & D, which is again driving innovation and growth in the market.

However, the market growth faces particular challenges. Lack of effective treatment is a significant cause restraining the market growth. There is no cure for the common cold, and existing treatments primarily focus on symptom relief rather than addressing the underlying viral infection. The acute rhinitis market is saturated with OTC products, making it challenging for new entrants to gain market share. Competition can lead to price pressures and limit profit margins. Prolonged use of certain OTC medications, such as decongestant nasal sprays, can lead to tolerance and reduced effectiveness, discouraging the patients from using it and restraining the market growth.

By Diagnosis & Treatment

  • Diagnosis
    • Nasal endoscopy
    • Imaging test
    • Laboratory test
    • Allergy testing
  • Treatment
    • Saline nasal spray
    • Nasal corticosteroids
    • Decongestants
    • OTC pain relievers
    • Allergy shots
    • Antibiotics

By End User

  • Hospitals & Clinics
  • Research Centers
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process. 

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. Asia-Pacific is set to experience favourable expansions and growth during the forecast period in the sinusitis treatment drugs market due to the increasing awareness about the diseases and rapid growth in bacterial and viral infections. North America dominates the market due to the high income of the countries, vulnerable sinusitis population, and advanced healthcare facilities.
  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Acute Sinusitis Market By Diagnosis &  Treatment, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Acute Sinusitis Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Acute Sinusitis Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Acute Sinusitis Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Acute Sinusitis Market, By Diagnosis & Treatment Historical Analysis and Forecast 2023-2031 (USD Million)

    •      1. Diagnosis
         1.1. Nasal endoscopy
         1.2. Imaging test
         1.3. Laboratory test
         1.4. Allergy testing
        2. Treatment
         2.1. Saline nasal spray
         2.2. Nasal corticosteroids
         2.3. Decongestants
         2.4. OTC pain relievers
         2.5. Allergy shots
         2.6. Antibiotics

  • 8.   Acute Sinusitis Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Hospitals & Clinics
        2. Research Centers
        3. Others

  • 9.   North America Acute Sinusitis Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Acute Sinusitis Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Acute Sinusitis Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Acute Sinusitis Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •   1. Sanofi
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Abbott
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Bayer AG
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Aurobindo Pharma
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Bristol Myers Squibb
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Merck KGaA
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. AstraZeneca
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Reddy’s Laboratories, Ltd.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Novartis AG
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10.GlaxoSmithKline plc.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11